Publications by authors named "Giulia Benevolo"

66Publications

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.

Lancet Haematol 2020 Jun 30;7(6):e456-e468. Epub 2020 Apr 30.

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(20)30099-5DOI Listing
June 2020

Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy.

Leuk Lymphoma 2020 07 24;61(7):1535-1547. Epub 2020 Feb 24.

Hematology, Department of Medicine and Surgery, University of Insubria, Varese, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1728752DOI Listing
July 2020

Myeloproliferative and lymphoproliferative disorders: State of the art.

Hematol Oncol 2020 Apr 27;38(2):121-128. Epub 2019 Dec 27.

UOC Ematologia Aziendale, Azienda Usl Toscana Nord Ovest, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2701DOI Listing
April 2020

JAK2V617F, CALR, and MPL Mutations and Bone Marrow Histology in Patients with Essential Thrombocythaemia.

Acta Haematol 2018 7;140(4):234-239. Epub 2018 Nov 7.

Section of Pathology, Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493970DOI Listing
June 2019

Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.

Hematol Oncol 2019 Apr 7;37(2):117-128. Epub 2018 Sep 7.

Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2539DOI Listing
April 2019

Current options to manage Waldenström's macroglobulinemia.

Expert Rev Hematol 2017 07 19;10(7):637-647. Epub 2017 Jun 19.

a Division of Hematology , AOU Città della Salute e della Scienza , Torino , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1339596DOI Listing
July 2017

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.

Am J Hematol 2017 Jan 12;92(1):37-41. Epub 2016 Nov 12.

Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Institute of Hematology and Clinical Oncology "L. and A. Seràgnoli", Sant'Orsola-Malpighi University Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24572DOI Listing
January 2017

Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly.

Br J Haematol 2016 07 28;174(1):160-2. Epub 2015 Oct 28.

Department of Haematology and Oncology, Città della Salute e della Scienza Hospital, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13758DOI Listing
July 2016

Novel CALR somatic mutations in essential thrombocythaemia.

Br J Haematol 2016 06 7;173(5):797-801. Epub 2015 Sep 7.

Section of Pathology, AO Città della Salute e della Scienza, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13638DOI Listing
June 2016

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

J Clin Oncol 2015 Oct 17;33(30):3459-66. Epub 2015 Aug 17.

Antonio Palumbo, Francesca Gay, Federica Cavallo, Alessandra Larocca, Francesca Donato, Chiara Cerrato, Luana Boccadifuoco, and Mario Boccadoro, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino; Giulia Benevolo, S.C. Ematologia A.O. Città della Salute e della Scienza di Torino; Tommasina Guglielmelli, University of Turin and San Luigi Hospital; Giovannino Ciccone, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino and CPO Piemonte, Torino; Francesco Di Raimondo, Ospedale Ferrarotto, Azienda Policlinico-OVE, University of Catania, Catania; Maria T. Petrucci, Sapienza University of Rome; Tommaso Caravita, Ematologia Ospedale S. Eugenio, Rome; Sara Pezzatti, Azienda Ospedaliera San Gerardo, Monza; Francesca Patriarca, DISM, University Hospital, Udine; Chiara Nozzoli, AOU Careggi, Florence; Donatella Vincelli, A.O "Bianchi-Melacrino-Morelli," Reggio Calabria; Pellegrino Musto, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Referral Cancer Center of Basilicata, Rionero in Vulture; Paolo Corradini, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano; Michele Cavo, Institute of Hematology and Medical Oncology "Seràgnoli," Bologna University School of Medicine S. Orsola's University Hospital, Bologna, Italy; Izhar Hardan, Meir Medical Center, Kfar-Saba; Arnon Nagler, Tel Aviv University, Chaim Sheba Medical Center, Tel-Hashomer, Israel; Roman Hajek, University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic; Michel Delforge, University Hospital Leuven, Leuven, Belgium; Zhinuan Yu and Christian Jacques, Celgene, Summit, NJ; and Meletios A. Dimopoulos, National and Kapodistrian University of Athens, School of Medicine, Alexandra Hospital, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.2466DOI Listing
October 2015

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

J Clin Oncol 2014 Mar 21;32(7):634-40. Epub 2014 Jan 21.

Antonio Palumbo, Sara Bringhen, Alessandra Larocca, Valeria Magarotto, Paola Omedé, Roberto Mina, Mario Boccadoro, and Giulia Benevolo, Azienda Ospedaliera (A.O.) Città della Salute e della Scienza di Torino; Daniela Gottardi, A.O. Ordine Mauriziano; Roberto Passera, San Giovanni Battista Hospital, University of Torino, Torino; Davide Rossi and Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Novara; Francesco Di Raimondo, Ferrarotto Hospital, University of Catania, Catania; Francesca Patriarca, A.O. Universitaria, Udine; Anna Levi and Maria Teresa Petrucci, Sapienza University of Rome; Luca Franceschini, Tor Vergata University Hospital, Rome; Iolanda Donatella Vincelli, A.O. Bianchi-Melacrino-Morelli, Reggio Calabria; Mariella Grasso, S. Croce e Carle Hospital, Cuneo; Renato Zambello, Università degli Studi di Padova, Padova; Vittorio Montefusco, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori Milano, University of Milano, Milan; Antonietta Pia Falcone, IRCCS Casa Sollievo della Sofferenza and Unità di Ematologia, San Giovanni Rotondo; Roberto Marasca, University of Modena, Modena; Fortunato Morabito, A.O. di Cosenza, Cosenza; Tommasina Guglielmelli, "S. Luigi Gonzaga" Hospital, Orbassano; Chiara Nozzoli, A.O. Universitaria Careggi, Firenze; Massimo Offidani, Ospedali Riuniti, Ancona; Roberto Ria, University of Bari "Aldo Moro" Medical School, Bari; Pellegrino Musto, IRCCS-Centro Regionale Oncologico Basilicata, Rionero in Vulture; and Michele Cavo, Università degli Studi di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.0023DOI Listing
March 2014

The risk of CNS involvement in aggressive lymphomas in the rituximab era.

Expert Rev Hematol 2013 Dec 30;6(6):643-52. Epub 2013 Oct 30.

Hematology, Città della Salute e della Scienza Hospital, Corso Bramante 88 10126, Torino, Italy.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/17474086.2013.85
Publisher Site
http://dx.doi.org/10.1586/17474086.2013.850896DOI Listing
December 2013

Extranodal lymphomas.

Rinsho Ketsueki 2013 Oct;54(10):1843-9

Hematology, Città della Salute e della Scienza Hospital.

View Article

Download full-text PDF

Source
October 2013

XVI. CNS prophylaxis in aggressive lymphomas: for whom and how.

Hematol Oncol 2013 Jun;31 Suppl 1:89-91

Hematology 2, Città della Salute e della Scienza Hospital, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2074DOI Listing
June 2013

Ten antibodies, six colors, twelve parameters: a multiparameter flow cytometric approach to evaluate leptomeningeal disease in B-cell non-Hodgkin's lymphomas.

Cytometry B Clin Cytom 2012 May 10;82(3):139-44. Epub 2012 Feb 10.

Flow Cytometry Unit, Department of Pathology, Molinette Hospital, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21001DOI Listing
May 2012